Luke Halpern, Associate Editor

Managing comorbidities, ensuring proper dosing, and treating IVIG-related adverse events are areas where pharmacists play a large role.

Some patients treated with prolonged courses of oral nirmatrelvir/ritonavir experienced long COVID symptom improvements, while others reported little to no changes in their symptoms.

ALG-801 could present new opportunities to improve treatment and management of patients with pulmonary arterial hypertension, a life-threatening condition.

These new regulatory developments put CUTX-101 on track to become the first FDA-approved treatment for patients with Menkes disease.

For patients with multiple myeloma who may experience an infection while receiving teclistamab, supplementation with intravenous immunoglobulin (IVIG) can help resolve and prevent serious complications.

The new designation for the selective PPAR⍺ antagonist follows positive phase 1b/2 clinical trial results.

Regulatory action could help patients with Hunter syndrome who have cognitive and behavioral complications and often do not have an effective treatment crossing the blood-brain barrier.

Data from a follow-up at 6 months show a reduced risk of all-cause mortality in heart attack patients with anemia who receive a liberal transfusion strategy compared with a restrictive one.

COVID-19 survivors deemed the most highly impacted and fearful also reported the lowest health-related quality of life scores, indicating an association.

Backed by positive results in multiple clinical trials, a new drug application (NDA) has been submitted for relacorilant for consideration by the FDA.

Treatment with IVIG leads to high responses 6 months following the initiation of therapy.

Pharmacists should be aware of the impacts that anemia in patients being treated for cancer has on daily activities and overall quality of life.

Over 70% of children and young people with long COVID reported improvements in their symptoms within 24 months of their initial positive SARS-CoV-2 test.

The regulatory decision marks a significant step forward in the treatment of non-tuberculous mycobacteria infections.

Constantine Tam, MD, discusses zanubrutinib's efficacy in CLL/SLL, emphasizing its durability, high response rates, safety considerations, and evolving therapeutic potential in combination with other agents.

Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.

Yi Lin, MD, PhD, highlights the importance of achieving MRD negativity in multiple myeloma, CAR T-cell therapy outcomes, and the critical role of pharmacists in patient care.

The monoclonal antibody demonstrates the ability to reduce the incidence and improve symptoms related to sleep disorders and psychiatric disorders such as anxiety.

Factors associated with intravenous immunoglobulin (IVIG)-related adverse events include older age, dehydration, and administration of multiple IVIG infusions.

Currently available for prescription in the United States, vibegron is now the first and only β3 agonist FDA approved to treat patients living with OAB and being treated for BPH.

The approval of the generic to liraglutide injection, currently in shortage, could help increase patient access to the type 2 diabetes treatment.

Clinical trials will seek to evaluate the immunogenicity and safety of the LBT-SA7 vaccine.

The new approval continues to expand the therapeutic potential of GLP-1 medications such as tirzepatide, now being deemed effective in patients with obstructive sleep apnea.

Knowing which patients are at higher risk for developing urticaria by analyzing their history of food allergies could lead to better outcomes in this population.

Proven effective in the treatment of atopic dermatitis (AD) and other allergic conditions, these study results confirm the ability of dupilumab to improve symptoms in children with other concurrent conditions.

Firas El Chaer, MD, discusses newly-presented data at ASH demonstrating nuvisertib's effectiveness in myelofibrosis.

Abstract data presented in September demonstrate that the drug elicited strong antitumor activity in the second line in both platinum-sensitive and -resistant patients.

Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.

Based on positive results from the HERCULES trial, the new designation will allow for more thorough regulatory review and development of the multiple sclerosis treatment.

The approval builds on previous indications for tapinarof, an aryl hydrocarbon receptor agonist, for the topical treatment of atopic dermatitis.